Pulmonary/Respiratory Medicine CME

Credits: 1.00 CME / MOC / CNE
Medical Learning Institute, Inc.
A New Era Has Begun in the Treatment of SCLC: Navigating Novel Therapeutic Options and Strategies for Improving Patient Outcomes
Stephen V. Liu, MD
29 May, 2019
Credits: 1.50 CME / MOC / CNE
Medical Learning Institute, Inc.
The Present and Future of Immunotherapy as a Key Component of the Treatment Arsenal for Locally Advanced & Earlier Stages of Lung Cancer
Leora Horn, MD, MSc, FRCPC
9 May, 2019
Credits: 1.50 CME / MOC / CNE
Medical Learning Institute, Inc.
Refining Current Practice and Exploring New Frontiers in EGFR-Mutant NSCLC: Evolving Science, New Standards of Care, and Implications for Multidisciplinary Management
Benjamin Levy, MD
17 April, 2019
Credits: 1.50 CME / MOC / CNE
Medical Learning Institute, Inc.
Addressing Unmet Needs in Earlier Stages of NSCLC With Immunotherapy: Cutting-Edge Research, Clinical Applications, and Practical Challenges
Scott Antonia, MD, PhD
15 April, 2019
Credits: 1.00 CME / MOC / CNE
Medical Learning Institute, Inc.
Exploring the Path Forward in Nontuberculous Mycobacterial Lung Disease: A MasterClass on Risk Factors, Diagnosis, and Treatment
David Griffith, MD
3 April, 2019
Credits: 1.00 CME / MOC / CNE
Medical Learning Institute, Inc.
Expanding Options and Difficult Choices in the Initial Treatment of Advanced NSCLC: How to Personalize Treatment Decisions in the Era of Immuno-Oncology and Combinations
Mark Socinski, MD
27 March, 2019
Credits: 1.50 CME
Medical Learning Institute, Inc.
Breaking the Paradox: Expanding Options and New Questions in HCC Management—Mapping the Pathways to Better Patient Outcomes
Richard Finn, MD
15 February, 2019
Credits: 1.00 CME / MOC
Medical Learning Institute, Inc.
Molecular Testing for EGFR Mutations in the Context of a Changing Treatment Landscape, Evolving Testing Options, and Updated Guidelines: What Pathologists Need to Know and Do
Lynette Sholl, MD
6 February, 2019
Credits: 1.00 CME / MOC / CE
Medical Learning Institute, Inc.
The Evolving Role of Immunotherapy as a Component of Multimodal Therapy in Earlier Stages of Lung Cancer: Rationale, Current Evidence, Key Trials, and Implications for Multidisciplinary Care
Naiyer Rizvi, MD
14 December, 2018
Credits: 1.50 CME / MOC
Medical Learning Institute, Inc.
Molecular Testing for EGFR Mutations in the Context of a Changing Treatment Landscape, Evolving Testing Options, and New Guidelines: What Pathologists Need to Know and Do
Lynette Sholl, MD
11 December, 2018
Credits: 1.50 CME
Medical Learning Institute, Inc.
The Era of Immunotherapy in Stage III NSCLC: Exploring the Evidence and Practicalities of Integrating Checkpoint Inhibition Into the Multimodal Treatment Arsenal
Roy Decker, MD, PhD
7 December, 2018
Credits: 1.00 CME / MOC
Medical Learning Institute, Inc.
Navigating the Complexities of Molecular Testing for EGFR Mutations to Guide Treatment Selection in Lung Cancer: Evidence, Practicalities, and Implications for Pathologists
Anjali Saqi, MD, MBA / Geoffrey R. Oxnard, MD
29 November, 2018
Credits: 1.50 CME / MOC / CE
Medical Learning Institute, Inc.
Improving Patient Outcomes With Cancer Immunotherapies Throughout the Lung Cancer Continuum: State of the Science and Implications for Practice
Edward Garon, MD, MS
22 November, 2018
Credits: 0.75 CME
National Jewish Health
Examining the IPF Patient’s Journey to Diagnosis, Appropriate Therapy, and Overall Individualized Care
Gary Cunningham
20 November, 2018
Credits: 0.50 CME
Medical Learning Institute, Inc.
Expert Insights on Available and Emerging Therapies for the Management of Pompe Disease
Loren del Mar Pena, MD, PhD
8 November, 2018
Credits: 1.00 CME
Medical Learning Institute, Inc.
A MasterClass on New Avenues in Asthma Management: Finding the Right Patients for Targeted Therapies
Jonathan Corren, MD
7 November, 2018
Credits: 0.50 CME
Medical Learning Institute, Inc.
Improving Care in ILD: Accurate Interpretation of HRCT and Advancing Therapies for Treatment
Luca Richeldi, MD, PhD
21 August, 2018
Credits: 0.50 CME
Medical Learning Institute, Inc.
Progressive Fibrosing Interstitial Lung Disease: Shining a Light on the Latest Clinical Advances
Kevin Flaherty, MD, MS
13 August, 2018
Credits: 0.50 CME
Penn State College of Medicine
Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD): Expert Insights on Current Management and Emerging Therapy
Kristin Highland, MD, MSCR
3 August, 2018
Credits: 1.50 CME
Medical Learning Institute, Inc.
Updates in Interstitial Lung Disease: Making Strides in Accurate Diagnosis and Optimized Treatment
Lisa Lancaster, MD
31 July, 2018
Credits: 1.50 CME
Medical Learning Institute, Inc.
Pulmonary Hypertension at the Crossroads of Current Clinical Challenges and Novel Therapeutic Strategies
Nick Kim, MD
31 July, 2018
Credits: 0.50 CME
Medical Learning Institute, Inc.
Exploring the Latest Data in the Treatment of Uncontrolled Persistent Asthma: Clinical Highlights From San Diego
Nicola Hanania, MD, MS
13 July, 2018
Credits: 1.50 CME
Medical Learning Institute, Inc.
Making the TRK to Precision Medicine in Cancer: The Promise of Targeting TRK Fusions in Lung, Breast, GI, and Other Tumors
George Demetri, MD
9 July, 2018
Credits: 2.00 CME
Medical Learning Institute, Inc.
Realizing the Potential of Precision Oncology in Lung Cancer—Challenges and Opportunities: Strengthening the Partnership Between Oncology and Pathology to Make the Most of the Latest Diagnostics and Therapies
Edward Garon, MD, MS
5 July, 2018
Credits: 0.50 CME
Medical Learning Institute, Inc.
Evaluating New Advances in Idiopathic Pulmonary Fibrosis and Other Interstitial Lung Diseases: Updates From San Diego
Fernando Martinez, MD, MS
27 June, 2018